Literature-reported formulation composition
Component: BiP-20 | mol%: 50 | Role: Ionizable lipid
sales@dcchemicals.com
BIP-20
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: DOPE | mol%: 10 | Role: Helper phospholipid
Literature-reported formulation composition
Component: Cholesterol | mol%: 38.5 | Role: Sterol
Literature-reported formulation composition
Component: DMPE-PEG2000 | mol%: 1.5 | Role: PEG lipid
Literature-reported formulation composition
Component: Reported total | mol%: 100 | Role: Source values retained
Table 2
Purpose: Selected for subsequent studies | BiP-20 / DOPE / cholesterol / DMPE-PEG2000 (mol%): 50 / 10 / 38.5 / 1.5 | Interpretation: BiP20-R; selected because the higher-mean BiP-20-19 group was more variable.
Table 2
Purpose: Initial lipid screening | BiP-20 / DOPE / cholesterol / DMPE-PEG2000 (mol%): 35 / 16 / 46.5 / 2.5 | Interpretation: 10:1 ionizable lipid:mRNA w/w explicitly reported for screening.
Table 2
Purpose: Highest mean in formulation screen | BiP-20 / DOPE / cholesterol / DMPE-PEG2000 (mol%): 45 / 16 / 38.5 / 0.5 | Interpretation: BiP-20-19: 1.72-fold vs BiP20-R at 4 h, n=3, p=0.0216.
Table 3
Helper lipid: DOPE | DLS diameter (nm): ~42 | PDI: ~0.14 | mRNA EE (%): ~98 | Reporter result: Stronger liver expression; n=3 mice
Table 3
Helper lipid: DSPC | DLS diameter (nm): ~40 | PDI: ~0.17 | mRNA EE (%): ~98 | Reporter result: Lower reporter expression; n=2 mice
Table 4
Cargo / endpoint: Cas9 + sgTTR / genomic indels | Dose and readout: 2 µg total RNA; day 7; n=4 | BiP-20 result: ~20% | Benchmark / interpretation: Genomic sequencing; separate from serum TTR protein
Table 4
Cargo / endpoint: Cas9 + sgTTR / genomic indels | Dose and readout: 10 µg total RNA; day 7; n=4 | BiP-20 result: ~64% | Benchmark / interpretation: LP01 ~30 µg for a comparable editing level
Table 4
Cargo / endpoint: Cas9 + sgTTR / serum TTR | Dose and readout: 1 µg total RNA; day 7; n=4 | BiP-20 result: ~50% reduction; p=0.0093 | Benchmark / interpretation: SI reports up to 40% indels; not a mean editing percentage
Table 4
Cargo / endpoint: PEmax + pegRNA + ngRNA / TTAC insertion | Dose and readout: Reported 50 µg/mouse; day 7; n=4 | BiP-20 result: 4.30% | Benchmark / interpretation: SM102 3.33%; MC3 1.33%; LP01 0.1225%
Reported observation
Literature-reported Hepatic FLuc expression 5.9-fold vs MC3 CD1; 3 µg FLuc mRNA IV; 4 h comparison, with 24 h also assessed; n=3 · Similar expression to SM102; not a claim of superiority over SM102 Main Fig.1f, PDF p.3; text p.4
Reported observation
Literature-reported TTR genomic editing ~64% indels 10 µg total Cas9 mRNA + sgTTR (1:1 w/w), IV; CD1 mice; day 7; n=4 · LP01 required ~30 µg total RNA for a comparable editing level Main Fig.1h and text, PDF pp.3–4
Reported observation
Literature-reported Low-dose TTR genomic editing ~20% indels 2 µg total Cas9 mRNA + sgTTR, IV; CD1; day 7; n=4 · Separate from the 10 µg condition and 1 µg SI experiment Main Fig.1h and text, PDF pp.3–4
Reported observation
Literature-reported Pcsk9 prime editing 4.30% TTAC insertion CD1; reported 50 µg RNA/mouse, IV; day 7; n=4; see dose wording note · SM102 3.33%; MC3 1.33%; LP01 0.1225%; significance reported vs MC3 and LP01 Main Fig.1j and text, PDF pp.3–4; SI Fig.S8, PDF p.10
Reported observation
Literature-reported Apparent LNP pKa 6.56 TNS titration, n=4; fit shown as 6.561; measured before composition optimization in the report · Formulation-dependent value; exact molar composition for this titration is not separately restated Main Fig.1e, PDF p.3; text p.4; TNS method p.12
Reported observation
Literature-reported LysoBC escape proxy ~8% at 30 min; ~6% at 1 h 5 µg modified DNA barcode IV; LysoTag mice; n=4 · Non-lysosomal flow-through / (flow-through + lysosomal) barcode reads; not an mRNA transfection percentage Main Fig.2j, PDF p.5; caption p.6; explanation p.7
Reported observation
RNA loading and manufacturing context The microfluidic method uses ethanol-solubilized lipids and pH-4 citrate RNA, aqueous:ethanol 3:1 v/v, and 12 mL/min total flow. The 10:1 mass ratio is explicitly tied to initial lipid:mRNA screening. No N/P ratio or separate selected-formulation ionizable-lipid:total-editing-RNA ratio is given. Main methods are reported laboratory conditions, not a validated product-specific manufacturing specification. · Main PDF pp.12–13
Reported observation
Endosomal escape: what the 8% measures LysoBC yielded approximately 8% at 30 min and 6% at 1 h. It compares DNA barcode reads in non-HA-bound flow-through against flow-through plus isolated HA-tagged endolysosomal reads. The authors treat this as a proxy for extra-lysosomal localization; it does not prove that every counted barcode supports productive delivery. 5 µg modified DNA barcode, IV; LysoTag mice; n=4. Cargo and assay differ from mRNA expression and editing studies. · Main Fig.2j, PDF pp.5–6; qualification p.7; SI Fig.S10, PDF p.12
Reported observation
ApoE / LDL-R dependence ApoE knockout nearly eliminated liver reporter signal, while LDL-R knockout substantially reduced it. These experiments support ApoE-dependent uptake with a contribution from LDL-R and potentially other receptors. C57BL/6, ApoE−/− and LDL-R−/− cohorts, n=3; reporter expression at 4 h and 24 h. This is an uptake-dependence result, not a measured receptor-specific endosomal escape rate. · Main PDF p.4; SI Fig.S6, PDF p.8
Reported observation
Acute tolerability under the tested condition At 50 µg total RNA per mouse and 24 h after IV retro-orbital administration, ALT and AST were comparable to untreated controls. BiP-20 did not significantly increase IL-6; TNFα was below the assay detection limit. Single-dose serum endpoints only. ALT/AST n=4; IL-6 treated groups n=4, untreated n=3. No claim of clinical, repeat-dose or long-term safety. · Main Safety profile, PDF p.7; SI Fig.S11, PDF p.13
Reported observation
Structure and chemical identity The SI identifies BiP-20 as O,O-bis(2-octyldodecyl)-N-(2-(dimethylamino)ethyl)phosphoramidate, formula C44H93N2O3P, MW 729.21 g/mol. It has two saturated branched C20 tails and a dimethylaminoethyl head attached through a phosphoramidate N–H. Identity is consistent with the existing DC68021 SMILES and formula; product specifications are retained. The SI reports synthesis and characterization, not a DC Chemicals batch COA. · Main Fig.1c, PDF p.3; SI PDF p.51 (printed p.50); BiP-20 NMR/HRMS SI PDF pp.137–139